Innate Pharma S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPHYF research report →
About the company
Innate Pharma S. A. , a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions.
- CEO
- Jonathan E. Dickinson
- IPO
- 2015
- Employees
- 181
- HQ
- Marseille, FR
Price Chart
- Market Cap
- $154.94M
- P/E
- -3.03
- P/S
- 56.07
- P/B
- -7.01
- EV/EBITDA
- -2.69
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2058.02%
- Net Margin
- -1764.51%
- ROE
- 593.93%
- ROIC
- -155.52%
- Revenue
- $2.79M · -77.93%
- Net Income
- $-49,158,581 · 0.63%
- EPS
- $-0.55 · 9.84%
- Op Income
- $-53,425,000
- FCF YoY
- -625.61%
- 52W High
- $2.25
- 52W Low
- $1.31
- 50D MA
- $1.70
- 200D MA
- $1.91
- Beta
- 0.88
- Avg Volume
- 127
Get TickerSpark's AI analysis on IPHYF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IPHYF coverage
Recent articles, reports, and earnings notes.
No research on IPHYF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IPHYF report →Similar companies
Peers in the same neighborhood.